BHVN - Biohaven Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$16.50
DETAILS
HIGH:
$23.00
LOW:
$10.00
MEDIAN:
$16.50
CONSENSUS:
$16.50
UPSIDE:
74.60%
About Biohaven Ltd. (https://www.biohaven.com)
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Vladimir Coric | Chairman & Chief Executive Officer | 1971 | $1,397,915 USD |
| Matthew Buten | Chief Financial Officer | 1961 | $858,610 USD |
| Bruce D. Car DACVP | Chief Scientific Officer | 1962 | $801,361 USD |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 1966 | $757,722 USD |
| Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer | – | – |
| Deb Young | Senior Director of Regulatory Affairs & Operations | – | – |
| George C. Clark | Vice President & Chief Accounting Officer | 1985 | – |
| Jennifer Porcelli | Vice President of Investor Relations | – | – |
| John McGill | Chief Technology Officer | – | – |
| John Tilton | Chief Commercial Officer of Rare Diseases | 1968 | – |
| Warren Volles | General Counsel & Chief Legal Officer | – | – |